SCHEMBL22912372

SCHEMBL22912372

BC(B)(CC(=O)O)C(B)(B)CC(CCSCc1ccccc1)SCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C19 P33261 3/20 0.46
▸ ALDH1A1 P00352 5/20 0.37
▸ HPGD P15428 5/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ PTGER1 P34995 1/20 0.36
▸ PTGER4 P35408 1/20 0.36
▸ PTGER3 P43115 1/20 0.36
▸ PTGER2 P43116 1/20 0.36
▸ MMP1 P03956 1/20 0.35
▸ MMP2 P08253 1/20 0.35
▸ MMP3 P08254 1/20 0.35
▸ MMP7 P09237 1/20 0.35
▸ MMP9 P14780 1/20 0.35
▸ MMP13 P45452 1/20 0.35
▸ ALPL P05186 1/20 0.34
▸ ALPI P09923 1/20 0.34
▸ ALPG P10696 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20395088 0.78 CYP2C19 (0.56) CYP2C19ALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL20395792 0.77 CYP2C19 (0.63) CYP2C19ALDH1A1HPGDSMN1; SMN2LMNA
Cpi 613 SCHEMBL13333201 0.75 CYP2C19 (0.59) CYP2C19ALDH1A1HPGDSMN1; SMN2LMNA
Cpi 613 SCHEMBL1062218 0.75 CYP2C19 (0.59) CYP2C19ALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL22299081 0.74 CYP2C19 (0.58) CYP2C19ALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL17381514 0.74 CYP2C19 (0.58) CYP2C19ALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL26613554 0.74 CYP2C19 (0.50) CYP2C19ALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL22912361 0.73 CYP2C19 (0.38) CYP2C19ALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL22912377 0.72 CYP2C19 (0.40) CYP2C19ALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL22912363 0.72 CYP2C19 (0.37) CYP2C19ALDH1A1HPGDSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348373-A1 DEUTERATED DERIVATIVES OF 6,8-BIS(BENZYLSULFANYL)OCTANOIC ACID RAFAEL PHARMACEUTICALS, INC. (US) 2023-11-02 — — US disclosed
WO-2021011334-A1 DEUTERATED DERIVATIVES OF 6,8-BIS(BENZYLSULFANYL)OCTANOIC ACID RAFAEL PHARMACEUTICALS, INC. (US) 2021-01-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348373-A1 DEUTERATED DERIVATIVES OF 6,8-BIS(BENZYLSULFANYL)OCTANOIC ACID SCD5, DHCR7, BCL6 CYP2C19 1131/4885ALDH1A1 1740/4885HPGD 629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback